Companies: 10,795·Total market cap: $144.5T
TG Therapeutics, Inc.

TG Therapeutics, Inc.

TGTXNASDAQHealthcare● Active
$41.30
+$1.14(+2.85%)
Market Cap$6.3B
P/E Ratio
52W High$44.65
52W Low$25.28
Overview

TG Therapeutics, Inc. (TGTX) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

tgtx · stock forecast · 13 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 13 Wall Street analysts in the past 3 months

SellBuy

Buy

13 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
11
Hold
1
Sell
1
Strong Sell
0
Total: 13 · Buy rate: 84.6%

12-Month Price Target

High

$70.00

Consensus

$54.50

+32.2% upside

Low

$39.00

Median: $54.5 · Last Close: $41.22

The TG Therapeutics, Inc. (TGTX) analyst consensus is Buy, based on ratings from 13 Wall Street analysts over the past 3 months. The average 12-month TGTX price target is $54.50, representing +32.2% upside from the current price of $41.22.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $55 (32.2%)

Consensus Target

$54.50

32.2% upside

High Target

$70

69.8%

Low Target

$39

-5.4%

Current Price

$41.22

as of today

Based on analyst price targets, the TGTX stock price prediction for the next 12 months ranges from $39 to $70. The consensus TGTX price forecast of $54.50 implies 32.2% upside from the current price of $41.22.

Short-Term Price Prediction

Bull

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$41.070.36%

1-day model range: $40.77–$41.37. Peak: $41.37 (-0.36%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$52+25.8%
2028$60+45.2%
2029$65+58.7%
2030$69+67.5%
2031+73.1%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

93%7%0%
13Buy
1Neutral
0Sell
RSI (14)58.2Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · TGTX · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$39.74BUY
MA 10$39.18BUY
MA 20$39.86BUY
MA 50$37.18BUY
MA 100$33.47BUY
MA 200$32.84BUY
Current $TGTX · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$40.10BUY
EMA 10$39.63BUY
EMA 20$39.21BUY
EMA 50$37.25BUY
EMA 100$35.17BUY
EMA 200$33.72BUY
Current $TGTX · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2026-05-27
Maintains
BuyBuy
HC Wainwright & Co.2026-05-06
Maintains
BuyBuy
JP Morgan2026-02-02
Maintains
OverweightOverweight
Goldman Sachs2026-01-15
Maintains
NeutralNeutral
JP Morgan2025-11-03
Maintains
OverweightOverweight
B. Riley Securities2025-09-17
Maintains
BuyBuy
HC Wainwright & Co.2025-03-04
Maintains
BuyBuy
HC Wainwright & Co.2025-01-15
Maintains
BuyBuy
JP Morgan2024-11-25
Maintains
OverweightOverweight
Goldman Sachs2024-11-05
Maintains
NeutralNeutral

Wall Street analysts have recently issued updated ratings on TG Therapeutics, Inc. (TGTX) stock. Of the recent 81 rating actions, 1 were upgrades and 2 were downgrades. 13 analysts currently cover TGTX.

Analyst Recommendation Trends

Buy ratings12↑ +1
Hold ratings00
Sell ratings00

TGTX analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$941M

↓ 41.3% YoY

Revenue Next Year

$1.2B

↑ 31.7% YoY

EPS This Year

$1.38

EPS Next Year

$2.53

↑ 83.5% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast TGTX EPS of $1.38 for the current fiscal year, based on estimates from 5 analysts. The TGTX revenue forecast is $941M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The TGTX stock forecast is supported by two independent data sources: analyst consensus ratings from 13 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus TGTX price target is $54.50 (+32.2% upside), with an analyst consensus of Buy.

The TGTX short-term stock prediction for tomorrow is $41.07 (-0.36%). The TGTX stock price prediction for 2027 estimates an average of $52. The TGTX stock prediction for 2030 projects a range of $64–$75.

TG Therapeutics, Inc. trades on NASDAQ under the ticker TGTX. The TGTX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 85% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

TGTX forecast · 8 questions

According to 13 Wall Street analysts, the average 12-month TGTX price target is $54.50, with a high forecast of $70.00 and a low of $39.00. The median price target is shown in the chart above when available. This implies +32.2% potential upside from the current price of $41.22.

TGTX price targetWhat is TGTX price targetTGTX analyst price targetTGTX 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.